THCA vs THCP: Understanding the Difference

THCP is the newest cannabinoid to generate real buzz in the hemp world, and the marketing around it leans hard on one eye-catching number: 33 times stronger than THC. That figure comes from a real 2019 Italian research paper, but the full story is a lot more nuanced than a bottle label can convey — and it matters enormously for anyone deciding what to actually put in their body. THCA, by contrast, is the cannabinoid nature makes in abundance, in every hemp plant, with a well-understood path from raw flower to activated THC. THCP exists in the plant too, but only in vanishingly small amounts — so small that virtually every commercial THCP product on the market today is synthesized in a lab, not extracted from cannabis. This guide walks through what THCP actually is, how the science of its discovery has been stretched by marketing, and why THCA remains the more transparent, better-understood, and more predictable choice.

What Is THCA?

THCA (tetrahydrocannabinolic acid) is the raw, non-intoxicating cannabinoid that hemp plants naturally biosynthesize in abundance in their trichomes — often making up 15% to 30%+ of dried flower by weight. THCA carries an extra carboxyl group that prevents it from effectively binding to CB1 receptors in the brain, which is why raw cannabis doesn't get you high. Apply heat through smoking, vaporizing, or baking, and THCA undergoes decarboxylation — losing that carboxyl group as CO2 and converting into Δ9-THC, the cannabinoid responsible for cannabis's classic psychoactive and therapeutic effects. This is a naturally occurring, high-abundance cannabinoid with a simple, one-step activation process and eighty-plus years of pharmacological research behind the molecule it becomes.

What Is THCP?

THCP, or tetrahydrocannabiphorol, was first isolated and identified in December 2019 by a team of Italian researchers led by Giuseppe Cannazza and Cinzia Citti at the University of Modena and Reggio Emilia, working with the CNR Institute of Nanotechnology in Lecce, Italy. Their findings were published in the journal Scientific Reports. The team was analyzing a medicinal cannabis variety called FM2, supplied by Italy's Military Chemical Pharmaceutical Institute in Florence, when they identified a previously unknown compound with the same core structure as THC but with a seven-carbon alkyl side chain instead of THC's standard five-carbon chain — two extra carbons that turned out to matter enormously.

That extra chain length is the whole story of THCP's potency. Cannabinoid researchers have long known that the length of the side chain attached to a THC-type molecule strongly influences how tightly it binds to CB1 receptors, with binding affinity generally increasing as the chain lengthens from three carbons up through about eight, then decreasing beyond that. In laboratory radioligand binding tests, the Italian team measured THCP's binding affinity for the human CB1 receptor at a Ki of 1.2 nanomolar — compared to roughly 40 nanomolar for standard Δ9-THC, making THCP roughly 33 times more potent at binding CB1 in that specific in vitro assay. In mouse studies using the standard "cannabinoid tetrad" behavioral test, THCP produced THC-like effects — reduced movement, pain relief, catalepsy, and lowered body temperature — at about half the dose needed to produce the same effects with THC.

Natural vs Commercial THCP

Here's the detail that most THCP marketing glosses over: in the original 2019 discovery, THCP was found in the FM2 cannabis variety at an extremely low concentration — so low that the researchers themselves noted in follow-up interviews that the amount present likely doesn't reach an effective dose on its own. Giuseppe Cannazza, the study's lead author, told Cannabis Business Times directly that his team didn't know at the time whether other cannabis varieties would produce more, since nobody had ever looked for a seven-carbon cannabinoid before. THCP is real, and it is naturally occurring — but it's a trace compound, not an abundant one, in stark contrast to THCA's routine 20%+ concentrations in hemp flower.

This creates an obvious supply problem for anyone trying to sell THCP commercially. Because naturally occurring THCP exists in such minuscule quantities, virtually every THCP product sold today — vapes, gummies, flower marketed as "THCP-infused" — relies on chemical synthesis rather than plant extraction to hit any meaningful concentration. A 2024 Forensic Chemistry study that tested three commercial THCP products (a flower sample, gummies, and a vape cartridge) purchased online found THCP concentrations in every sample that differed significantly from what the packaging claimed, and the same analysis also detected other unlisted semi-synthetic cannabinoids, including HHC, mixed in with the products. This is the fundamental difference from THCA: THCA at 20%+ concentration is simply what the plant naturally makes, full stop, while THCP at commercially meaningful concentration requires a synthesis process that isn't standardized, isn't consistently disclosed on labels, and — as that 2024 study demonstrates — isn't always accurately represented on the COA you're shown before buying.

Effects Comparison

THCA-derived THC produces the classic, well-mapped cannabis experience: euphoria, relaxation, altered sensory perception, and appetite stimulation, with intensity that scales predictably with the percentage listed on a COA and decades of user experience to calibrate expectations against. Because dosing information has accumulated over more than half a century of research and legal use, first-time and experienced users alike have a reasonably reliable sense of what a given THC percentage will feel like.

THCP's dramatically higher CB1 binding affinity means the effective dose is much smaller than what people are used to with THC — but "smaller effective dose" cuts both ways. It also means the margin between a comfortable dose and an overwhelming one is much narrower, and there is nowhere near the accumulated user experience or research base to calibrate expectations the way there is with THC. The original 2019 study's own animal data found THCP fully replicated THC's tetrad effects at roughly half the THC dose — a meaningfully larger effect per milligram, but based entirely on mouse behavioral testing, not controlled human trials. No published human clinical studies on THCP dosing, tolerance, or subjective effects existed as of this writing, which means real-world dosing guidance for THCP products is largely improvised by manufacturers and users through trial and error rather than grounded in actual research.

The Potency Problem With THCP Products

The "33 times stronger" claim is accurate as a description of one specific lab measurement — CB1 receptor binding affinity in an in vitro radioligand assay — but it is regularly stretched by marketing copy into an implied claim about real-world potency that the original research doesn't actually support. Binding affinity measures how tightly a molecule attaches to a receptor in a controlled lab setting; it doesn't directly translate into "33 times the high" once you account for bioavailability, how a compound is metabolized, how much of it actually reaches the bloodstream when smoked or vaporized, and how the body's receptors respond to sustained versus brief activation.

This gap between lab measurement and consumer expectation creates real overconsumption risk. If a product is marketed as dramatically more potent than THC but doesn't clearly communicate just how small the corresponding dose needs to be, users accustomed to typical THC serving sizes can easily consume far more THCP than intended, especially in vape or edible formats where the actual per-unit dose isn't always disclosed clearly or accurately — a real problem, as the 2024 Forensic Chemistry testing of commercial products demonstrated. Because there's no established human dosing research to anchor serving size recommendations, manufacturers are essentially guessing at appropriate doses, and consumers are the ones absorbing that uncertainty.

Safety and Research

THC and THCA benefit from over sixty years of continuous scientific study since Mechoulam's 1964 structural elucidation of THC — thousands of pharmacological, toxicological, and clinical papers covering dosing, drug interactions, long-term use patterns, and risk profiles across diverse populations. That depth of research is precisely why THCA-derived THC products can be labeled, dosed, and used with a reasonable degree of predictability.

THCP's entire published research base, by contrast, consists of a small number of papers, starting with the original 2019 isolation study and followed by a handful of analytical chemistry papers (like the 2024 Forensic Chemistry product-testing study) focused on detecting and quantifying THCP in commercial products rather than studying its safety or physiological effects in humans. There are no published human clinical trials examining THCP's safety profile, long-term effects, drug interactions, or appropriate dosing in people. Every safety-relevant data point that exists comes from a single mouse behavioral study. That's simply not enough evidence to make confident safety claims one way or the other — which is itself the point: THCP's risk profile is genuinely unknown, not proven-safe and not proven-dangerous, and treating it as either overstates what the science currently supports.

Drug Testing Implications

THCP is structurally a THC analog, and it's reasonable to expect that its metabolic breakdown produces THC-like metabolites that could trigger a positive result on a standard cannabis drug test — but this hasn't been directly confirmed in any published human metabolism study specific to THCP. This puts THCP in an even less-studied position than HHC when it comes to drug test predictability; researchers have at least begun mapping HHC's metabolite profile and immunoassay cross-reactivity in small human trials, while equivalent human data for THCP does not yet exist in the published literature. If you're subject to drug testing of any kind, the safest working assumption is that any THC-analog cannabinoid, including THCP, carries real risk of a positive result, even without confirmed metabolite data to quantify that risk precisely.

Other Long-Chain Cannabinoids Worth Knowing

THCP wasn't discovered in isolation. The same University of Modena research group that identified THCP also isolated CBDP (cannabidiphorol), the seven-carbon homolog of CBD, in the same 2019 paper. Unlike THCP, CBDP doesn't show strong binding affinity for CB1 or CB2 receptors, mirroring CBD's own non-intoxicating profile, so it hasn't attracted the same commercial hype. More recently, researchers have also identified THCB (tetrahydrocannabutol, the four-carbon homolog) and THCH (tetrahydrocannabihexol, the six-carbon homolog) as naturally occurring trace cannabinoids in cannabis. THCB showed roughly threefold higher CB1 binding affinity than THC in a 2019 study but with in vivo effects broadly comparable to standard THC, while THCH's affinity hasn't been as thoroughly characterized because it occurs in even smaller natural quantities than THCP.

The pattern across this entire family of long-chain cannabinoids is consistent: each one was first identified as a trace natural compound, each generated a wave of commercial interest once its receptor binding data was published, and each is now sold commercially almost entirely as a synthesized product rather than a plant extract, since none of them occur in cannabis at concentrations anywhere close to what a consumer product needs. If you see a hemp product marketed around any cannabinoid with an unfamiliar three- or four-letter abbreviation and a headline potency multiplier, it's worth asking the same questions you'd ask about THCP: is this naturally abundant or lab-synthesized, and how much actual human safety research backs up the marketing claim?

How to Evaluate Any New Cannabinoid Claim

THCP is unlikely to be the last cannabinoid to generate a wave of "X times stronger than THC" marketing, so it's worth having a general framework for evaluating these claims as new compounds inevitably emerge. Start by asking where the potency figure actually comes from — a binding affinity measurement (Ki value) from an in vitro radioligand assay is a different kind of evidence than a human dose-response study, and marketing copy frequently blurs the two together. Next, check whether the compound is naturally abundant in the plant or requires synthesis to reach commercial concentrations; abundance affects both the reliability of sourcing and the likelihood that a manufacturer's synthesis process introduces its own variability and contaminant risk. Finally, look for the existence — or absence — of human research entirely separate from animal studies, since rodent tetrad tests are a standard first step in cannabinoid pharmacology but were never intended to substitute for human safety data.

Applying that framework to THCP specifically: the potency figure comes from an in vitro binding assay, not a human trial; the compound requires synthesis to reach any commercially meaningful concentration; and there is no published human research on its effects, safety, or appropriate dosing. None of that makes THCP a scam or inherently unsafe — it makes it an open scientific question that the market has run well ahead of the research answering it.

Why Natural THCA Is the Smarter Choice

Setting aside the marketing hype, the practical case for THCA comes down to a few concrete advantages. First, transparency: a THCA percentage on a COA reflects exactly what the plant produced, with a well-understood one-step conversion to THC — no synthesis process to introduce variability between what's on the label and what's actually in the product, unlike the discrepancies documented in commercial THCP testing. Second, predictability: THC's effects at a given dose are backed by decades of accumulated research and real-world use, letting you reasonably anticipate what a given percentage will feel like, where THCP dosing is still essentially guesswork extrapolated from a single mouse study. Third, safety research: THC's risk profile, including its well-documented downsides, has been studied for over half a century, while THCP's has not been studied in humans at all. Fourth, sourcing integrity: because THCA doesn't need to be manufactured to reach an effective concentration, there's no synthesis supply chain in which contaminants, mislabeled potency, or unlisted secondary cannabinoids can creep in — problems that independent lab testing has already documented in the commercial THCP market. None of this means THCP is necessarily dangerous — it means the honest answer is "we don't know yet," and until that changes, THCA remains the more evidence-backed, transparent option for anyone who wants to understand what they're actually consuming.

Legal Status of THCP in 2026

THCP occupies a similarly ambiguous legal position to HHC, and for related reasons. Because the 2018 Farm Bill defines legal hemp based on Δ9-THC concentration rather than naming every possible cannabinoid, THCP derived from hemp technically falls within the letter of federal law in most interpretations — but several states have moved to close that gap by broadening their definitions of controlled substances to include THC analogs and isomers regardless of source. Unlike THCA, which is now explicitly addressed in many state hemp regulations because it's so ubiquitous in the market, THCP's regulatory treatment varies more unpredictably from state to state, in part because the compound is newer and less familiar to state legislators drafting hemp policy.

This creates a practical problem for consumers: a THCP product might be technically unregulated in one state simply because lawmakers haven't gotten around to addressing it yet, not because anyone has affirmatively decided it's safe or appropriate for retail sale. That's a meaningfully different kind of "legal" than THCA's status, which has been directly and repeatedly addressed in hemp legislation across most states that regulate hemp products at all. If you're ordering THCP products online, don't assume legality in your state mirrors legality anywhere else, and don't assume the absence of a specific ban means the product has been vetted by anyone.

The Marketing Gap Between Lab Data and Store Shelves

It's worth sitting with how quickly THCP went from an obscure 2019 academic discovery to a shelf product marketed with bold potency claims, because that speed is itself informative. Compare it to THC: Mechoulam identified THC's structure in 1964, and it took decades of subsequent pharmacological research, clinical trials, and regulatory engagement before THC-based medicines like Marinol reached patients through a formal approval process. THCP, by contrast, went from a single academic paper describing preliminary mouse data straight to commercial gummies, vapes, and flower sprays within about two to three years, with no comparable clinical development process in between.

That compressed timeline reflects the current reality of the hemp cannabinoid market more than it reflects any judgment about THCP's actual safety. Because the 2018 Farm Bill created a legal pathway for hemp-derived products without requiring the kind of premarket safety review that pharmaceutical cannabinoids go through, manufacturers can bring a newly discovered compound to market almost as soon as its chemistry is published, well before its safety profile is understood. This is precisely the gap that makes independent lab verification and a healthy skepticism toward big potency claims so important for anyone shopping in this category — the regulatory system isn't doing the safety-vetting work that consumers might reasonably assume it's doing.

Frequently Asked Questions

Is THCP really 33 times stronger than THC?

That figure comes from a specific 2019 lab measurement of CB1 receptor binding affinity (Ki=1.2nM for THCP vs. roughly 40nM for THC), not a direct measurement of real-world potency in humans. Binding affinity is one factor among several — including bioavailability and metabolism — that determine actual subjective effects, and no human studies have confirmed a 33x real-world potency difference.

Is THCP natural or synthetic?

THCP does occur naturally in cannabis, but only in extremely small trace amounts, as discovered in the original 2019 Italian study. Because natural concentrations are too low to be commercially practical, virtually all THCP sold in consumer products today is produced through chemical synthesis rather than plant extraction.

Has THCP been tested in humans?

No published human clinical trials on THCP exist as of this writing. The only safety and effects data available comes from a single 2019 mouse behavioral study and subsequent analytical chemistry papers focused on detecting THCP in commercial products, not studying its effects in people.

Are commercial THCP products accurately labeled?

Not reliably. A 2024 study published in Forensic Chemistry tested three commercial THCP products and found actual THCP concentrations differed significantly from what was listed on packaging, and also detected unlisted cannabinoids like HHC mixed into the products.

Will THCP show up on a drug test?

It's reasonable to assume so, since THCP is structurally a THC analog, but no published human study has directly confirmed THCP's metabolite profile or drug test cross-reactivity. Treat it as a likely positive result if you're subject to testing.

Why does Ember Trees sell THCA flower instead of THCP products?

THCA is naturally abundant in hemp flower, requires only a simple heat-based conversion to become active, and is backed by decades of cannabinoid research. THCP requires lab synthesis to reach commercial potency, has essentially no human safety research, and current testing shows inconsistent labeling accuracy across commercial products.

Choose the Cannabinoid With the Evidence Behind It

THCP is a genuinely interesting scientific discovery, but "interesting in a 2019 mouse study" and "ready for confident everyday consumer use" are two very different things. THCA offers what THCP currently can't: natural abundance, a simple and well-understood activation process, transparent labeling, and a cannabinoid — THC — with more than half a century of research behind it. None of this requires distrust of cannabis science generally; if anything, it requires more trust in it, since the entire case for caution around THCP comes directly from the same research tradition that first identified the compound. Following the evidence where it currently stands means recognizing that abundant, well-studied, transparently labeled THCA flower is the more responsible choice today, even as research on newer cannabinoids continues to develop.

Shop THCA flower at Ember Trees to explore lab-verified strains with full COA transparency, or visit the Ember Trees blog for more cannabinoid science explained in plain language.